Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape
Medical Sciences · 16.11.2026 · 14 (7) · 789
DOI: 10.3390/medsci14070789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 16.11.2026. Verfasst von Alexandru-Florinel Oancea und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) develops through cooperation between altered hepatocytes, chronic liver injury and a stromal and immune microenvironment. Genomic alterations and signaling abnormalities provide a rationale for treatment development, but pathway activation rarely identifies therapeutic dependence alone. This narrative review connects hepatic stellate cell states, tumor cell plasticity, genomic instability and four selected signaling pathways with antigen presentation, immune exclusion and clinical treatment evidence. Targeted searches were updated through 6 October 2026, retaining foundational work and prioritizing recent studies. Single-cell and spatial analyses reveal that stellate cells and cancer-associated fibroblasts can exert opposing effects according to their state and location. Similarly, CTNNB1-associated signaling can favor immune exclusion, but mutation status does not fully capture immune context or establish universal resistance to checkpoint combinations. Intratumoral dendritic cell and lymphocyte organization, suppressive myeloid niches and humoral responses provide complementary explanations of treatment heterogeneity. Randomized trials support selected antiangiogenic and checkpoint combinations in unresectable HCC, while negative trials and updated adjuvant results demonstrate the limits of extrapolating biological rationale across regimens and disease stages. The synthesis distinguishes experimental causality, patient-level association and clinically validated benefit. Translation requires compartment-specific target assessment, representative sampling and prospective biomarker evaluation within a defined treatment setting, alongside assessment of liver reserve.
Zitieren
APA
Oancea, A., Leonard, M., Botnariu, G., Miftode, I., Burlacu, A., Vâță, A., Crăciun, G., Rotaru, A., Mitea, R., Tanase, D. M., Cojocaru, E., & Floria, M. (2026). Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape. Medical Sciences, 14(7), 789. https://doi.org/10.3390/medsci14070789
Vancouver
Oancea A, Leonard M, Botnariu G, Miftode I, Burlacu A, Vâță A, et al. Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape. Medical Sciences. 2026;14(7):789. doi:10.3390/medsci14070789
BibTeX
@article{Oancea2026,
author = {Oancea, Alexandru-Florinel and Leonard, Mathilde and Botnariu, Gina and Miftode, Ionela-Larisa and Burlacu, Alexandru and Vâță, Andrei and Crăciun, Gabriela and Rotaru, Alexandra and Mitea, Raluca and Tanase, Daniela Maria and Cojocaru, Elena and Floria, Mariana},
title = {Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {7},
pages = {789},
doi = {10.3390/medsci14070789}
}
EUVIMED